Shots:
- The EC has approved Mynzepli (AVT06), a biosimilar version of Eylea (aflibercept) for all indications of the reference product in all 30 EEA states; AVT06’s Dossiers are under review in multiple regions incl. the US & Japan
- Approval was based on extensive analytical, non-clinical & clinical data incl. a confirmatory study assessing Mynzepli vs Eylea in neovascular AMD, which met its 1EP, showing similar efficacy, safety, & immunogenicity between the two
- Mynzepli targets VEGF to inhibit receptor activation, neovascularization, & vascular permeability, which is available as a 40mg/mL solution for injection in a pre-filled syringe & a vial
Ref: Alvotech | Image: Alvotech & Advanz Pharma | Press Release
Related News:- Alvotech Partners with Advanz Pharma to Commercialize AVT10 (Biosimilar, Cimzia) in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
